Turkey Hande Demirdere, general manager of Pierre Fabre Pharma in Turkey, sheds light on the affiliate’s impressive 93 percent growth in 2017 while highlighting where to target development opportunities in the dynamic Turkish market. In this interview, the experienced General Manager discusses the advantages of diversifying strategies, Pierre Fabre’s comparative advantage…
Turkey Mustafa Kemal Erol , president of the Turkish Society of Cardiology, introduces one of the oldest and largest societies in the country divulges their best collaborations with the Ministry of Health in the country, in addition to offering a deep analysis of his assessment of the cardiology landscape, and why…
Cyprus Constantinos Ioannou, the recently appointed Minister of Health for Cyprus, discusses the upcoming implementation of a national healthcare system in the country, GeSY, his key priorities during these times of change, as well as the impact the new healthcare system will have on the public and the private sector. You…
Cyprus Michael Neoptolemou, managing director at Remedica, takes us through the evolution of one of the leading pharmaceutical companies in Cyprus and outlines their successful business model. Neoptolemou also highlights the key opportunities the recent acquisition by Ascendis Health in 2016 has brought to Remedica and how it will further enhance…
UK Richard Erwin, general manager of Roche Products Ltd in the UK, speaks out about the challenges facing the company, from market access to uptake of innovation, to collaborating with diverse stakeholder groups, improving outcomes for UK patients. We do see a will and an intent from stakeholders, from government…
Cyprus Pantis Papaloizou, managing director of the family company CG Papaloisou Ltd, gives his insights on the healthcare changes that will happen in Cyprus and their impact for local importers of innovative medicines. He also highlights the key role of Papaloisou in the local market and how he plans to strengthen…
UK Geoff Twist, managing director of Roche Diagnostics UK and Ireland, analyses the changing mindset he sees at various levels, leaning towards greater recognition of pathology’s impact on health systems. He further highlights some exciting paths Roche Diagnostics is embarking on, such as digital pathology and widened molecular screening programmes. After…
Pharma What is VR and why should healthcare and pharmaceutical companies take note? VR (Virtual Reality) places the user into a virtual world. VR differs from Augmented Reality (AR), which sets virtual objects against the backdrop of the real world—as in Pokemon Go, the augmented reality smartphone craze of 2016—or simply…
UK With four out of the five NHS bodies, Leeds City Region is strongly anchored in the British life sciences ecosystem. Chair of Leeds City Region Enterprise Partnership, Roger Marsh OBE, highlights what else makes the region special: its great talent, dedication to discovery and ability to build bridges between academia…
UK Heading the Life Sciences strategy for Scotland’s main economic development agency Scottish Enterprise, Julia Brown recalls some of the region’s unique features making it an ideal place for life Sciences investment: a historic focus on research and interest in clinical trials, great talent from world-class universities, as well as an…
Spain Antonio Bernal, president of the General Patient Alliance (AGP), discusses the role of the patient voice in the Spanish healthcare system and how the alliance is the bridge between the patient associations and the administration. Furthermore, he highlights the evolution of the Alliance and how the strength of the patients…
Turkey Dr. Uğur Baran, general secretary of OHSAD – Turkey’s Private Hospital and Health Organizations Association – highlights how he is striving to keep open the dialogue between the association and the government over key issues such as reimbursement policy, the role of private hospitals for the country and how partnerships…
See our Cookie Privacy Policy Here